Trial Profile
A Multiple Patient Expanded Access Program for Olaparib Tablets for the Maintenance Treatment Following Response (Complete Response or Partial Response) to Platinum-based Chemotherapy in Patients With Platinum-sensitive Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 27 Oct 2017
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 16 Mar 2017 New trial record